Skip to content
Screener

NeoGenomics NEO Reportable Segment — Total stock-based compensation

Similar metrics at other companies

Avalo Therapeutics logo
AVTXReportable Segment — Total stock-based compensation
$1.68M+50.5%
Applovin Corporation logo
APPReportable Segment — Total stock-based compensation
$85.78M+148%
Cytek Biosciences, Inc. logo
CTKBReportable Segment — Total stock-based compensation
$5.34M-21.4%
Sweetgreen logo
SGReportable Segment — Total stock-based compensation
$5.18M-35.3%
Akamai Technologies logo
AKAMReportable Segment — Total stock-based compensation
$146.29M+29.7%
Roku, Inc. logo
ROKUDevices — Total stock-based compensation
$87K-49.4%

Other financials

Income statement

See full
Revenue$201.7M+11.2%
Gross profit$91.9M+18.9%
Operating income-$9.8M+79.5%
Net income$2.2M+105%
EPS (diluted)$0.02+106%

Balance sheet

See full
Cash & equivalents$145.5M-5.9%
Total debt$448.4M+534%
Total equity$785.7M-8.0%
Total assets$1.4B-3.0%

Cash flow

See full
Operating cash flow$20.0M-1.8%
CapEx$8.2M+30.0%
Free cash flow-$13.1M+56.0%

Valuation

See full
Market cap$2B+182%
Enterprise value$2.3B+268%
P/S2.6×+1.6×

Profitability

See full
Gross margin43.9%0.0pp
Operating margin-8.9%-2.8pp
Net margin-6.8%-2.4pp
FCF margin-4.9%

Returns & leverage

See full
Return on equity-6.3%-2.0pp
Debt / equity0.6×+0.5×
Current ratio3.6×-0.3×

Where this comes from

Reported directly by NeoGenomics in its filing.

Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.

The source filing: NeoGenomics’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 4:09 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001077183-26-000059
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Cost of revenue$400$302$737$718
General and administrative6,91210,40815,30419,190
Research and development3196758961,272
Sales and marketing5858309151,788
Total stock-based compensation$8,216$12,215$17,852$22,968

Item 1. Financial Statements (unaudited)

FAQ

What is NeoGenomics's reportable segment — total stock-based compensation?
NeoGenomics (NEO) reported reportable segment — total stock-based compensation of $8.22M in Q2 2026.
How has NeoGenomics's reportable segment — total stock-based compensation changed year-over-year?
NeoGenomics's reportable segment — total stock-based compensation decreased by 32.7% year-over-year, from $12.22M to $8.22M.
What is the long-term trend for NeoGenomics's reportable segment — total stock-based compensation?
Over 3 years (2022 to 2025), NeoGenomics's reportable segment — total stock-based compensation has grown at a 18.8% compound annual growth rate (CAGR), from $24.67M to $41.32M.
What does reportable segment — total stock-based compensation mean?
The total expense recognized for equity-based awards granted to employees and management within the segment. This metric is critical for evaluating the true cost of human capital and the potential dilution impact on existing shareholders.

Ask your AI about NeoGenomics's reportable segment — total stock-based compensation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude